VolitionRX Limited (NYSEAMERICAN:VNRX) Sees Significant Decrease in Short Interest

VolitionRX Limited (NYSEAMERICAN:VNRX) was the recipient of a large decrease in short interest during the month of September. As of September 15th, there was short interest totaling 1,004,963 shares, a decrease of 54.8% from the August 31st total of 2,224,050 shares. Based on an average trading volume of 1,733,578 shares, the days-to-cover ratio is currently 0.6 days. Approximately 7.9% of the company’s stock are sold short.

VolitionRX Price Performance

VNRX stock traded down $0.01 during mid-day trading on Monday, reaching $0.25. The company had a trading volume of 905,955 shares, compared to its average volume of 3,126,849. The company has a market capitalization of $3.45 million, a price-to-earnings ratio of -0.07 and a beta of 1.10. VolitionRX has a 52 week low of $0.23 and a 52 week high of $14.80. The stock has a 50 day simple moving average of $0.55 and a two-hundred day simple moving average of $1.83.

VolitionRX (NYSEAMERICAN:VNRX) last released its quarterly earnings data on Thursday, August 13th. The medical research company reported ($0.85) EPS for the quarter, missing the consensus estimate of ($0.57) by ($0.28). The firm had revenue of $0.40 million during the quarter, compared to the consensus estimate of $0.41 million. On average, equities analysts predict that VolitionRX will post -1.88 EPS for the current year.

Analyst Ratings Changes

VNRX has been the topic of a number of recent research reports. Maxim Group reiterated a “buy” rating and issued a $4.00 price objective on shares of VolitionRX in a report on Thursday, June 18th. Benchmark reaffirmed a “hold” rating on shares of VolitionRX in a research report on Monday, August 17th. Two analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company’s stock. According to data from MarketBeat, VolitionRX presently has an average rating of “Hold” and a consensus target price of $28.00.

About VolitionRX

VolitionRx Limited is a life sciences company developing blood-based diagnostic tests for cancer and other diseases. The company’s technology is based on nucleosomes, fragments of DNA and associated proteins released into the bloodstream during cell death, which may provide information useful for disease detection, monitoring and treatment decisions.

VolitionRx’s product development activities include its Nu.Q technology platform and Nu.Q Vet, a suite of veterinary cancer screening and monitoring tests designed for use in dogs and other companion animals.